Close Menu

NEW YORK — Abingdon Health said on Thursday that a rapid point-of-care SARS-CoV-2 antibody test developed by a consortium of UK companies and the University of Oxford has received the CE mark.

According to Abingdon, the AbC-19TM Rapid Test is designed to detect immunoglobulin G antibodies against SARS-CoV-2 in a finger prick blood sample, with results available in 20 minutes without the need for laboratory analysis.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

This webinar will present a case study from in vitro diagnostics developer SpeeDx on its experience building a complete sample-to-result workflow — encompassing instrumentation and data analysis software — for its qPCR-based ResistancePlus MG Mycoplasma genitalium assay.

Sponsored by

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.